October 2016

New Product - Acarizax

Acarizax (Dermatophagoides pteronyssinus and Dermatophagoides farinae) is an allergy immunotherapy. Allergy immunotherapy with allergen products is the repeated administration of allergens to allergic individuals with the purpose of modifying the immunological response to the allergen to provide sustained underlying protection during subsequent allergen exposure. Acarizax is for the treatment of patients with specific IgE‑mediated allergy symptoms induced by house dust mites (HDM) such as allergic rhinitis and/or allergic asthma. Acarizax works by modifying the immune response to house dust mite (D. pteronyssinus and D. farinae) allergens and provides specific desensitization. Acarizax is indicated for the treatment of adults diagnosed with house dust mite allergic rhinitis not well controlled despite use of symptom relieving medication or HDM allergic asthma not well controlled by inhaled corticosteroids and associated with HDM allergic rhinitis. Patients’ asthma status should be carefully evaluated before the initiation of treatment. Acarizax is contraindicated in the following patients: with a FEV1 less than 70% of predicted value (after adequate pharmacological treatment) at initiation of treatment; who have experienced a severe asthma exacerbation within the last 3 months; with asthma and experiencing an acute respiratory tract infection, initiation of Acarizax treatment should be postponed until the infection has resolved; with active or poorly controlled autoimmune diseases, immunodeficiencies, immunosuppression or malignant neoplastic disease; and with acute severe oral inflammation or oral wounds. Acarizax is available as oral lyophilisate tablets containing a total of 12 SQ‑HDM (6 SQ‑HDM of D. pteronyssinus and 6 SQ‑HDM D. farinae) (the unit SQ‑HDM has been defined to measure the potency of Acarizax and is based on a standardised amount of allergens from each species) in packs of 90’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au